Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

Statins, a major class of drugs for treatment of hypercholesterolemia, are widely used due to a notable prevention of cardiovascular disease, and accumulating evidence proposes a promising role of statins in breast cancer

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Collaborator: Fayoum oncology Center
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

1. Confirmed breast cancer any stage confirmed by radiological and pathological or by clinical evaluation undergo surgery or receiving neo/adjuvant chemotherapy treatment

2. Age above 18 years

3. HER2 negative core biopsy

4. Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min

5. Patients must be accessible for treatment and follow-up

6. Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2

Exclusion Criteria:

1. Known hypersensitivity reaction to the investigational compounds or incorporated substances

2. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism, cardiac arrhythmia)